Ben is a psychiatrist, scientist, and investor who has been working at GV since 2014. Ben’s investments focus on healthcare delivery and neuropsychiatric therapeutics and include Aspire (acquired by Anthem), Rodin (acquired by Alkermes), Ready, Carebridge, and Cerevance.
Ben received his M.D. from Harvard Medical School, MBA from Harvard Business School, and B.A. with honors from Dartmouth College, where he was a member of the football team.